COVID-19 studies:  C19 studies: C19:  IvermectinIVM Vitamin DV.D HC QHC Q Vitamin CV.C ZincZn BHBH FPVFPV FLVFLV PVP-IPI REGNR2 LY-CoVLY RMDRMD
HCQ study #63 of 264
6/17 Early treatment study
Capucci et al., J. Cardiovasc. Med. 21, 922–923, doi:10.2459/JCM.0000000000001061 (Peer Reviewed)
Low hospitalization rate without severe arrhythmias: a prospective survey on 350 patients early home treated with hydroxychloroquine during COVID-19 pandemic
Source   PDF   Share   Tweet
Prospective analysis of early treatment of 350 patients in Italy (without waiting for PCR results), showing low hospitalization rates and no serious adverse events.
From 274 patients treated with HCQ, 16 required hospitalization (5.8%). Minor complications (mainly gastrointestinal, diarrhoea) were found in eight patients (2.9%), none of whom had to interrupt treatment. No major cardiac complications were found.
Of the 76 patients treated with HCQ+AZ, 4 were hospitalized (5.2%). Minor complications occurred in two patients (2.6%). There were no reports of any major arrhythmias, syncope or sudden death.

Capucci et al., 6/17/2020, peer-reviewed, 7 authors.
Details of all 264 studies    Meta analysis
Please send us corrections, updates, or comments.